{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:32:24Z","timestamp":1740123144279,"version":"3.37.3"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s11033-023-08326-3","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T11:55:39Z","timestamp":1677758139000},"page":"4535-4549","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of P11 through serotonergic and glutamatergic pathways in LID"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8388-7799","authenticated-orcid":false,"given":"Alireza","family":"Noori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4123-225X","authenticated-orcid":false,"given":"Kousha","family":"Farhadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5796-2049","authenticated-orcid":false,"given":"Yasmin","family":"Mohtasham Kia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7705-7783","authenticated-orcid":false,"given":"Nastaran","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8555-726X","authenticated-orcid":false,"given":"Soraya","family":"Mehrabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"issue":"1","key":"8326_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41531-018-0058-0","volume":"4","author":"C Marras","year":"2018","unstructured":"Marras C, Beck JC, Bower JH, Roberts E, Ritz B, Ross GW et al (2018) Prevalence of Parkinson\u2019s disease across North America. npj Parkinson\u2019s Dis 4(1):21","journal-title":"npj Parkinson's Dis"},{"issue":"18 Suppl 1","key":"8326_CR2","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1212\/WNL.0b013e3181fb3628","volume":"75","author":"JF Morley","year":"2010","unstructured":"Morley JF, Hurtig HI (2010) Current understanding and management of Parkinson disease: five new things. Neurology 75(18 Suppl 1):S9-15","journal-title":"Neurology"},{"key":"8326_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40035-017-0099-z","volume":"6","author":"P Maiti","year":"2017","unstructured":"Maiti P, Manna J, Dunbar GL (2017) Current understanding of the molecular mechanisms in Parkinson\u2019s disease: targets for potential treatments. Transl neurodegener 6:28","journal-title":"Transl neurodegener"},{"issue":"12","key":"8326_CR4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11910-013-0409-5","volume":"13","author":"L Marsh","year":"2013","unstructured":"Marsh L (2013) Depression and Parkinson\u2019s disease: current knowledge. Curr Neurol Neurosci Rep 13(12):409","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"3","key":"8326_CR5","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/j.1750-3639.2010.00373.x","volume":"20","author":"GS Watson","year":"2010","unstructured":"Watson GS, Leverenz JB (2010) Profile of cognitive impairment in Parkinson\u2019s disease. Brain Pathol 20(3):640\u2013645","journal-title":"Brain Pathol"},{"issue":"6","key":"8326_CR6","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.neuron.2019.03.004","volume":"101","author":"MM McGregor","year":"2019","unstructured":"McGregor MM, Nelson AB (2019) Circuit mechanisms of Parkinson\u2019s disease. Neuron 101(6):1042\u20131056","journal-title":"Neuron"},{"key":"8326_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.brainres.2013.03.027","volume":"1512","author":"T Taniwaki","year":"2013","unstructured":"Taniwaki T, Yoshiura T, Ogata K, Togao O, Yamashita K, Kida H et al (2013) Disrupted connectivity of motor loops in Parkinson\u2019s disease during self-initiated but not externally-triggered movements. Brain Res 1512:45\u201359","journal-title":"Brain Res"},{"key":"8326_CR8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.neuropsychologia.2015.09.017","volume":"77","author":"AR Sch\u00f6nberger","year":"2015","unstructured":"Sch\u00f6nberger AR, Hagelweide K, Pelzer EA, Fink GR, Schubotz RI (2015) Motor loop dysfunction causes impaired cognitive sequencing in patients suffering from Parkinson\u2019s disease. Neuropsychologia 77:409\u2013420","journal-title":"Neuropsychologia"},{"issue":"3","key":"8326_CR9","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3390\/ijms18030551","volume":"18","author":"R Cacabelos","year":"2017","unstructured":"Cacabelos R (2017) Parkinson\u2019s disease: from pathogenesis to pharmacogenomics. Int J Mol Sci 18(3):551","journal-title":"Int J Mol Sci"},{"issue":"1","key":"8326_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2174\/1389202914666131210213042","volume":"15","author":"J Dorszewska","year":"2014","unstructured":"Dorszewska J, Prendecki M, Lianeri M, Kozubski W (2014) Molecular effects of l-dopa therapy in Parkinson\u2019s disease. Curr Genomics 15(1):11\u201317","journal-title":"Curr Genomics"},{"issue":"5","key":"8326_CR11","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1073\/pnas.1524387113","volume":"113","author":"R Marongiu","year":"2016","unstructured":"Marongiu R, Arango-Lievano M, Francardo V, Morgenstern P, Zhang X, Cenci MA et al (2016) Gene therapy blockade of dorsal striatal p11 improves motor function and dyskinesia in parkinsonian mice. Proc Natl Acad Sci USA 113(5):1423\u20131428","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"8326_CR12","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1073\/pnas.0711839105","volume":"105","author":"X Zhang","year":"2008","unstructured":"Zhang X, Andren PE, Greengard P, Svenningsson P (2008) Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism. Proc Natl Acad Sci USA 105(6):2163\u20132168","journal-title":"Proc Natl Acad Sci USA"},{"key":"8326_CR13","volume-title":"Gene Therapy in neurological disorders","author":"R Marongiu","year":"2018","unstructured":"Marongiu R, Joyce JL, Kaplitt MG (2018) Chapter 9\u2013p11 gene therapy as a novel target for treatment of symptoms and medication complications in parkinson\u2019s disease. In: Li M, Snider BJ (eds) Gene Therapy in neurological disorders. Academic Press, Cambridge"},{"key":"8326_CR14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.expneurol.2013.09.003","volume":"250","author":"H Iderberg","year":"2013","unstructured":"Iderberg H, Rylander D, Bimpisidis Z, Cenci MA (2013) Modulating mGluR5 and 5-HT1A\/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action. Exp Neurol 250:116\u2013124","journal-title":"Exp Neurol"},{"issue":"6","key":"8326_CR15","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1007\/s12035-018-1356-6","volume":"56","author":"JR Garc\u00eda-Montes","year":"2019","unstructured":"Garc\u00eda-Montes JR, Sol\u00eds O, Enr\u00edquez-Traba J, Ruiz-DeDiego I, Drucker-Col\u00edn R, Moratalla R (2019) Genetic knockdown of mGluR5 in striatal D1R-containing neurons attenuates L-DOPA-induced dyskinesia in aphakia mice. Mol Neurobiol 56(6):4037\u20134050","journal-title":"Mol Neurobiol"},{"key":"8326_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.coph.2018.03.003","volume":"38","author":"I Sebastianutto","year":"2018","unstructured":"Sebastianutto I, Cenci MA (2018) mGlu receptors in the treatment of Parkinson\u2019s disease and L-DOPA-induced dyskinesia. Curr Opin Pharmacol 38:81\u201389","journal-title":"Curr Opin Pharmacol"},{"issue":"7","key":"8326_CR17","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.bcp.2013.08.005","volume":"86","author":"G Riahi","year":"2013","unstructured":"Riahi G, Morissette M, Samadi P, Parent M, Di Paolo T (2013) Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia. Biochem Pharmacol 86(7):970\u2013978","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"8326_CR18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00424-007-0313-4","volume":"455","author":"U Rescher","year":"2008","unstructured":"Rescher U, Gerke V (2008) S100A10\/p11: family, friends and functions. Pflugers Arch 455(4):575\u2013582","journal-title":"Pflugers Arch"},{"issue":"7","key":"8326_CR19","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.7150\/ijbs.33773","volume":"15","author":"G Liu","year":"2019","unstructured":"Liu G, Wang Y, Zheng W, Cheng H, Zhou R (2019) P11 Loss-of-Function is associated with decreased cell proliferation and neurobehavioral disorders in mice. Int J Biol Sci 15(7):1383\u20131395","journal-title":"Int J Biol Sci"},{"issue":"10","key":"8326_CR20","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrn3564","volume":"14","author":"P Svenningsson","year":"2013","unstructured":"Svenningsson P, Kim Y, Warner-Schmidt J, Oh YS, Greengard P (2013) p11 and its role in depression and therapeutic responses to antidepressants. Nat Rev Neurosci 14(10):673\u2013680","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"8326_CR21","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s00213-018-4872-1","volume":"235","author":"M Tiger","year":"2018","unstructured":"Tiger M, Varn\u00e4s K, Okubo Y, Lundberg J (2018) The 5-HT(1B) receptor\u2014a potential target for antidepressant treatment. Psychopharmacology 235(5):1317\u20131334","journal-title":"Psychopharmacology"},{"issue":"1\u20133","key":"8326_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00726-001-0131-5","volume":"23","author":"JM Wieronska","year":"2002","unstructured":"Wieronska JM, Szewczyk B, Branski P, Palucha A, Pilc A (2002) Antidepressant-like effect of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist in the olfactory bulbectomized rats. Amino Acids 23(1\u20133):213\u2013216","journal-title":"Amino Acids"},{"issue":"12","key":"8326_CR23","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1038\/mp.2015.132","volume":"20","author":"KW Lee","year":"2015","unstructured":"Lee KW, Westin L, Kim J, Chang JC, Oh YS, Amreen B et al (2015) Alteration by p11 of mGluR5 localization regulates depression-like behaviors. Mol Psychiatry 20(12):1546\u20131556","journal-title":"Mol Psychiatry"},{"issue":"11","key":"8326_CR24","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/S1474-4422(10)70218-0","volume":"9","author":"P Calabresi","year":"2010","unstructured":"Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N, Picconi B (2010) Levodopa-induced dyskinesias in patients with Parkinson\u2019s disease: filling the bench-to-bedside gap. Lancet Neurol 9(11):1106\u20131117","journal-title":"Lancet Neurol"},{"issue":"3","key":"8326_CR25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4103\/aian.AIAN_239_17","volume":"20","author":"S Pandey","year":"2017","unstructured":"Pandey S, Srivanitchapoom P (2017) Levodopa-induced Dyskinesia: clinical features, pathophysiology, and medical management. Ann Indian Acad Neurol 20(3):190\u2013198","journal-title":"Ann Indian Acad Neurol"},{"issue":"2","key":"8326_CR26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/14728214.2020.1763954","volume":"25","author":"S AlShimemeri","year":"2020","unstructured":"AlShimemeri S, Fox SH, Visanji NP (2020) Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update. Expert Opin Emerg Drugs 25(2):131\u2013144","journal-title":"Expert Opin Emerg Drugs"},{"key":"8326_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.07.002","volume":"132","author":"MF Bastide","year":"2015","unstructured":"Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M et al (2015) Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson\u2019s disease. Prog Neurobiol 132:96\u2013168","journal-title":"Prog Neurobiol"},{"key":"8326_CR28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.neuroscience.2011.07.070","volume":"198","author":"M Carta","year":"2011","unstructured":"Carta M, Bezard E (2011) Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia. Neuroscience 198:245\u2013251","journal-title":"Neuroscience"},{"issue":"Suppl 3","key":"8326_CR29","doi-asserted-by":"publisher","first-page":"S509","DOI":"10.1002\/mds.22021","volume":"23","author":"SH Fox","year":"2008","unstructured":"Fox SH, Lang AE (2008) Levodopa-related motor complications\u2013phenomenology. Mov Disord 23(Suppl 3):S509\u2013S514","journal-title":"Mov Disord"},{"key":"8326_CR30","doi-asserted-by":"publisher","first-page":"S263","DOI":"10.1016\/S1353-8020(08)70014-2","volume":"13","author":"MA Cenci","year":"2007","unstructured":"Cenci MA (2007) L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment. Parkinsonism Relat Disord 13:S263\u2013S267","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"8326_CR31","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrn2471","volume":"9","author":"P Jenner","year":"2008","unstructured":"Jenner P (2008) Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 9(9):665\u2013677","journal-title":"Nat Rev Neurosci"},{"issue":"8","key":"8326_CR32","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/nn.3743","volume":"17","author":"P Calabresi","year":"2014","unstructured":"Calabresi P, Picconi B, Tozzi A, Ghiglieri V, Di Filippo M (2014) Direct and indirect pathways of basal ganglia: a critical reappraisal. Nat Neurosci 17(8):1022\u20131030","journal-title":"Nat Neurosci"},{"issue":"10","key":"8326_CR33","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1002\/mds.21475","volume":"22","author":"G Fabbrini","year":"2007","unstructured":"Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG (2007) Levodopa-induced dyskinesias. Mov Dis 22(10):1379\u20131389","journal-title":"Mov Dis"},{"issue":"8","key":"8326_CR34","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s00702-018-1865-5","volume":"125","author":"M Carta","year":"2018","unstructured":"Carta M, Bj\u00f6rklund A (2018) The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective. J Neural Transm 125(8):1195\u20131202","journal-title":"J Neural Transm"},{"issue":"Pt 12","key":"8326_CR35","first-page":"3380","volume":"131","author":"A Mu\u00f1oz","year":"2008","unstructured":"Mu\u00f1oz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T et al (2008) Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. J of Neurol 131(Pt 12):3380\u20133394","journal-title":"J of Neurol"},{"key":"8326_CR36","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3389\/fneur.2014.00242","volume":"5","author":"MA Cenci","year":"2014","unstructured":"Cenci MA (2014) Presynaptic mechanisms of l-DOPA-induced Dyskinesia: the findings, the debate, and the therapeutic implications. Front Neurol 5:242","journal-title":"Front Neurol"},{"issue":"6","key":"8326_CR37","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ana.25364","volume":"84","author":"AJ Espay","year":"2018","unstructured":"Espay AJ, Morgante F, Merola A, Fasano A, Marsili L, Fox SH et al (2018) Levodopa-induced dyskinesia in Parkinson disease: current and evolving concepts. Ann Neurol 84(6):797\u2013811","journal-title":"Ann Neurol"},{"issue":"13","key":"8326_CR38","doi-asserted-by":"publisher","first-page":"4728","DOI":"10.1523\/JNEUROSCI.2702-13.2014","volume":"34","author":"T Fieblinger","year":"2014","unstructured":"Fieblinger T, Sebastianutto I, Alcacer C, Bimpisidis Z, Maslava N, Sandberg S et al (2014) Mechanisms of dopamine D1 receptor-mediated ERK1\/2 activation in the parkinsonian striatum and their modulation by metabotropic glutamate receptor type 5. J Neurosci 34(13):4728\u20134740","journal-title":"J Neurosci"},{"key":"8326_CR39","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fnagi.2018.00262","volume":"10","author":"WW Wang","year":"2018","unstructured":"Wang WW, Zhang XR, Zhang ZR, Wang XS, Chen J, Chen SY et al (2018) Effects of mGluR5 antagonists on Parkinson\u2019s patients with L-Dopa-induced dyskinesia: a systematic review and meta-analysis of randomized controlled trials. Front Aging Neurosci 10:262","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"8326_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1001\/archneurol.2009.287","volume":"67","author":"MA Brodsky","year":"2010","unstructured":"Brodsky MA, Park BS, Nutt JG (2010) Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease. Arch Neurol 67(1):27\u201332","journal-title":"Arch Neurol"},{"issue":"3","key":"8326_CR41","first-page":"161","volume":"12","author":"ML Martini","year":"2019","unstructured":"Martini ML, Neifert SN, Mocco J, Panov F, Tse W, Walker RH et al (2019) Recent advances in the development of experimental therapeutics for levodopa-induced Dyskinesia. J Mov Dis 12(3):161\u2013165","journal-title":"J Mov Dis"},{"key":"8326_CR42","first-page":"1","volume":"4","author":"I Martins","year":"2017","unstructured":"Martins I (2017) Nutrition therapy regulates caffeine metabolism with relevance to NAFLD and induction of type 3 diabetes. J Diabetes Metab Disord 4:1\u20139","journal-title":"J Diabetes Metab Disord"},{"issue":"5","key":"8326_CR43","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s12640-021-00392-4","volume":"39","author":"Y Chen","year":"2021","unstructured":"Chen Y, Jiang Y, Yang Y, Huang X, Sun C (2021) SIRT1 protects dopaminergic neurons in parkinson\u2019s disease models via PGC-1\u03b1-mediated mitochondrial biogenesis. Neurotox Res 39(5):1393\u20131404","journal-title":"Neurotox Res"},{"issue":"6","key":"8326_CR44","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.14336\/AD.2020.0216","volume":"11","author":"X Li","year":"2020","unstructured":"Li X, Feng Y, Wang XX, Truong D, Wu YC (2020) The critical role of SIRT1 in Parkinson\u2019s disease: mechanism and therapeutic considerations. Aging Dis 11(6):1608\u20131622","journal-title":"Aging Dis"},{"key":"8326_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.683577","volume":"12","author":"CQ Zheng","year":"2021","unstructured":"Zheng CQ, Fan HX, Li XX, Li JJ, Sheng S, Zhang F (2021) Resveratrol alleviates levodopa-induced dyskinesia in rats. Front Immunol 12:683577","journal-title":"Front Immunol"},{"issue":"1","key":"8326_CR46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.coph.2006.10.001","volume":"7","author":"P Svenningsson","year":"2007","unstructured":"Svenningsson P, Greengard P (2007) p11 (S100A10)\u2013an inducible adaptor protein that modulates neuronal functions. Curr Opin Pharmacol 7(1):27\u201332","journal-title":"Curr Opin Pharmacol"},{"issue":"4","key":"8326_CR47","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/cne.24113","volume":"525","author":"A Milosevic","year":"2017","unstructured":"Milosevic A, Liebmann T, Knudsen M, Schintu N, Svenningsson P, Greengard P (2017) Cell- and region-specific expression of depression-related protein p11 (S100a10) in the brain. J Comp Neurol 525(4):955\u2013975","journal-title":"J Comp Neurol"},{"issue":"10","key":"8326_CR48","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1073\/pnas.1621218114","volume":"114","author":"H Green","year":"2017","unstructured":"Green H, Zhang X, Tiklova K, Volakakis N, Brodin L, Berg L et al (2017) Alterations of p11 in brain tissue and peripheral blood leukocytes in Parkinson\u2019s disease. Proc Natl Acad Sci USA 114(10):2735\u20132740","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"8326_CR49","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.tips.2020.04.004","volume":"41","author":"JS Seo","year":"2020","unstructured":"Seo JS, Svenningsson P (2020) Modulation of Ion Channels and Receptors by p11 (S100A10). Trends Pharmacol Sci 41(7):487\u2013497","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"8326_CR50","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1017\/S1461145711000940","volume":"15","author":"PA Melas","year":"2012","unstructured":"Melas PA, Rogdaki M, Lennartsson A, Bj\u00f6rk K, Qi H, Witasp A et al (2012) Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression. Int J Neuropsychopharmacol 15(5):669\u2013679","journal-title":"Int J Neuropsychopharmacol"},{"issue":"5757","key":"8326_CR51","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.1117571","volume":"311","author":"P Svenningsson","year":"2006","unstructured":"Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, El Yacoubi M et al (2006) Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 311(5757):77\u201380","journal-title":"Science"},{"key":"8326_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2016.02.010","volume":"196","author":"SW Park","year":"2016","unstructured":"Park SW, Nhu LH, Cho HY, Seo MK, Lee CH, Ly NN et al (2016) p11 mediates the BDNF-protective effects in dendritic outgrowth and spine formation in B27-deprived primary hippocampal cells. J Affect Disord 196:1\u201310","journal-title":"J Affect Disord"},{"key":"8326_CR53","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fncel.2015.00064","volume":"9","author":"F Ng","year":"2015","unstructured":"Ng F, Wijaya L, Tang BL (2015) SIRT1 in the brain-connections with aging-associated disorders and lifespan. Front Cell Neurosci 9:64","journal-title":"Front Cell Neurosci"},{"key":"8326_CR54","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4236\/aar.2016.51002","volume":"5","author":"I Martins","year":"2016","unstructured":"Martins I (2016) Anti-Aging Genes Improve Appetite Regulation and Reverse Cell Senescence and Apoptosis in Global Populations. Adv Aging Res 5:9\u201326","journal-title":"Adv Aging Res"},{"issue":"1\u20132","key":"8326_CR55","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s11010-012-1509-2","volume":"374","author":"S Sayeed","year":"2013","unstructured":"Sayeed S, Asano E, Ito S, Ohno K, Hamaguchi M, Senga T (2013) S100A10 is required for the organization of actin stress fibers and promotion of cell spreading. Mol Cell Biochem 374(1\u20132):105\u2013111","journal-title":"Mol Cell Biochem"},{"issue":"12","key":"8326_CR56","first-page":"1858","volume":"11","author":"SY Hsu","year":"1997","unstructured":"Hsu SY, Kaipia A, Zhu L, Hsueh AJ (1997) Interference of BAD (Bcl-xL\/Bcl-2-associated death promoter)-induced apoptosis in mammalian cells by 14-3-3 isoforms and P11. Mol Endocrinol 11(12):1858\u20131867","journal-title":"Mol Endocrinol"},{"issue":"6","key":"8326_CR57","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1523\/JNEUROSCI.5343-08.2009","volume":"29","author":"JL Warner-Schmidt","year":"2009","unstructured":"Warner-Schmidt JL, Flajolet M, Maller A, Chen EY, Qi H, Svenningsson P et al (2009) Role of p11 in cellular and behavioral effects of 5-HT4 receptor stimulation. J Neurosci 29(6):1937\u20131946","journal-title":"J Neurosci"},{"issue":"5","key":"8326_CR58","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1073\/pnas.1524303113","volume":"113","author":"N Schintu","year":"2016","unstructured":"Schintu N, Zhang X, Alvarsson A, Marongiu R, Kaplitt MG, Greengard P et al (2016) p11 modulates L-DOPA therapeutic effects and dyskinesia via distinct cell types in experimental Parkinsonism. Proc Natl Acad Sci USA 113(5):1429\u20131434","journal-title":"Proc Natl Acad Sci USA"},{"key":"8326_CR59","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fncir.2014.00021","volume":"8","author":"C Miguelez","year":"2014","unstructured":"Miguelez C, Morera-Herreras T, Torrecilla M, Ruiz-Ortega JA, Ugedo L (2014) Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson\u2019s disease. Front Neural Circuit 8:21","journal-title":"Front Neural Circuit"},{"key":"8326_CR60","doi-asserted-by":"publisher","first-page":"172914","DOI":"10.1016\/j.ejphar.2020.172914","volume":"871","author":"C Kwan","year":"2020","unstructured":"Kwan C, Frouni I, B\u00e9dard D, Hamadjida A, Huot P (2020) Ondansetron, a highly selective 5-HT(3) receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson\u2019s disease. Eur J Pharmacol 871:172914","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"8326_CR61","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/j.1471-4159.2011.07598.x","volume":"120","author":"A Nahimi","year":"2012","unstructured":"Nahimi A, H\u00f8ltzermann M, Landau AM, Simonsen M, Jakobsen S, Alstrup AK et al (2012) Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning. J Neurochem 120(5):806\u2013817","journal-title":"J Neurochem"},{"issue":"10","key":"8326_CR62","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1212\/WNL.57.10.1829","volume":"57","author":"F Bibbiani","year":"2001","unstructured":"Bibbiani F, Oh JD, Chase TN (2001) Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 57(10):1829\u20131834","journal-title":"Neurology"},{"key":"8326_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2022.114209","volume":"358","author":"M Thomsen","year":"2022","unstructured":"Thomsen M, Stoica A, Christensen KV, Fryland T, Mikkelsen JD, Hansen JB (2022) Synergistic effect of serotonin 1A and serotonin 1B\/D receptor agonists in the treatment of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats. Exp Neurol 358:114209","journal-title":"Exp Neurol"},{"key":"8326_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108771","volume":"198","author":"R Tohge","year":"2021","unstructured":"Tohge R, Kaneko S, Morise S, Oki M, Takenouchi N, Murakami A et al (2021) Zonisamide attenuates the severity of levodopa-induced dyskinesia via modulation of the striatal serotonergic system in a rat model of Parkinson\u2019s disease. Neuropharmacology 198:108771","journal-title":"Neuropharmacology"},{"issue":"10","key":"8326_CR65","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/syn.20941","volume":"65","author":"C Marin","year":"2011","unstructured":"Marin C, Bonastre M, Aguilar E, Jim\u00e9nez A (2011) The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L-DOPA-induced dyskinesias. Synapse 65(10):1080\u20131086","journal-title":"Synapse"},{"issue":"6","key":"8326_CR66","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/1440-1681.12410","volume":"42","author":"A Ferrigno","year":"2015","unstructured":"Ferrigno A, Vairetti M, Ambrosi G, Rizzo V, Richelmi P, Blandini F et al (2015) Selective blockade of mGlu5 metabotropic glutamate receptors is protective against hepatic mitochondrial dysfunction in 6-OHDA lesioned Parkinsonian rats. Clin Exp Pharmacol Physiol 42(6):695\u2013703","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"18","key":"8326_CR67","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.3390\/ijms20184391","volume":"20","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Zhang S, Fu P, Zhang Z, Lin K, Ko JK et al (2019) Roles of Glutamate Receptors in Parkinson\u2019s Disease. Int J Mol Sci 20(18):4391","journal-title":"Int J Mol Sci"},{"key":"8326_CR68","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.neuropharm.2016.03.036","volume":"115","author":"N Litim","year":"2017","unstructured":"Litim N, Morissette M, Di Paolo T (2017) Metabotropic glutamate receptors as therapeutic targets in Parkinson\u2019s disease: An update from the last 5 years of research. Neuropharmacology 115:166\u2013179","journal-title":"Neuropharmacology"},{"key":"8326_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107725","volume":"158","author":"I Frouni","year":"2019","unstructured":"Frouni I, Hamadjida A, Kwan C, B\u00e9dard D, Nafade V, Gaudette F et al (2019) Activation of mGlu2\/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism. Neuropharmacology 158:107725","journal-title":"Neuropharmacology"},{"key":"8326_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.172957","volume":"873","author":"L Sid-Otmane","year":"2020","unstructured":"Sid-Otmane L, Hamadjida A, Nuara SG, B\u00e9dard D, Gaudette F, Gourdon JC et al (2020) Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset. Eur J Pharmacol 873:172957","journal-title":"Eur J Pharmacol"},{"key":"8326_CR71","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fnmol.2019.00020","volume":"12","author":"R Crupi","year":"2019","unstructured":"Crupi R, Impellizzeri D, Cuzzocrea S (2019) Role of Metabotropic Glutamate Receptors in Neurological Disorders. Front Mol Neurosci 12:20","journal-title":"Front Mol Neurosci"},{"issue":"3","key":"8326_CR72","doi-asserted-by":"publisher","first-page":"959","DOI":"10.3233\/JPD-191824","volume":"10","author":"E Mann","year":"2020","unstructured":"Mann E, Jackson M, Lincoln L, Fisher R, Rose S, Duty S (2020) Antiparkinsonian Effects of a Metabotropic Glutamate Receptor 4 Agonist in MPTP-Treated Marmosets. J Parkinsons Dis 10(3):959\u2013967","journal-title":"J Parkinsons Dis"},{"issue":"9","key":"8326_CR73","doi-asserted-by":"publisher","first-page":"948","DOI":"10.7150\/ijbs.6426","volume":"9","author":"SS Willard","year":"2013","unstructured":"Willard SS, Koochekpour S (2013) Glutamate, glutamate receptors, and downstream signaling pathways. Int J Biol Sci 9(9):948\u2013959","journal-title":"Int J Biol Sci"},{"key":"8326_CR74","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.phrs.2016.11.013","volume":"115","author":"FM Ribeiro","year":"2017","unstructured":"Ribeiro FM, Vieira LB, Pires RG, Olmo RP, Ferguson SS (2017) Metabotropic glutamate receptors and neurodegenerative diseases. Pharmacol Res 115:179\u2013191","journal-title":"Pharmacol Res"},{"issue":"1\u20132","key":"8326_CR75","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.brainresbull.2010.01.011","volume":"82","author":"G Ambrosi","year":"2010","unstructured":"Ambrosi G, Armentero MT, Levandis G, Bramanti P, Nappi G, Blandini F (2010) Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson\u2019s disease. Brain Res Bull 82(1\u20132):29\u201338","journal-title":"Brain Res Bull"},{"key":"8326_CR76","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.neuropharm.2012.07.036","volume":"66","author":"N Morin","year":"2013","unstructured":"Morin N, Gr\u00e9goire L, Morissette M, Desrayaud S, Gomez-Mancilla B, Gasparini F et al (2013) MPEP, an mGlu5 receptor antagonist, reduces the development of l-DOPA-induced motor complications in de novo parkinsonian monkeys: Biochemical correlates. Neuropharmacology 66:355\u2013364","journal-title":"Neuropharmacology"},{"issue":"4","key":"8326_CR77","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3390\/cells11040691","volume":"11","author":"M Morissette","year":"2022","unstructured":"Morissette M, Bourque M, Tremblay M, Di Paolo T (2022) Prevention of L-Dopa-Induced Dyskinesias by MPEP Blockade of Metabotropic Glutamate Receptor 5 Is Associated with Reduced Inflammation in the Brain of Parkinsonian Monkeys. Cells 11(4):691","journal-title":"Cells"},{"key":"8326_CR78","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.neurobiolaging.2017.09.006","volume":"61","author":"M Crabb\u00e9","year":"2018","unstructured":"Crabb\u00e9 M, Van der Perren A, Weerasekera A, Himmelreich U, Baekelandt V, Van Laere K et al (2018) Altered mGluR5 binding potential and glutamine concentration in the 6-OHDA rat model of acute Parkinson\u2019s disease and levodopa-induced dyskinesia. Neurobiol Aging 61:82\u201392","journal-title":"Neurobiol Aging"},{"issue":"2","key":"8326_CR79","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1042\/BST20140006","volume":"42","author":"MA Cenci","year":"2014","unstructured":"Cenci MA (2014) Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson\u2019s disease. Biochem Soc Trans 42(2):600\u2013604","journal-title":"Biochem Soc Trans"},{"issue":"2","key":"8326_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.21","volume":"6","author":"HL Sun","year":"2016","unstructured":"Sun HL, Zhou ZQ, Zhang GF, Yang C, Wang XM, Shen JC et al (2016) Role of hippocampal p11 in the sustained antidepressant effect of ketamine in the chronic unpredictable mild stress model. Transl Psychiatry 6(2):e741","journal-title":"Transl Psychiatry"},{"key":"8326_CR81","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.neubiorev.2018.05.021","volume":"92","author":"MM Conti","year":"2018","unstructured":"Conti MM, Chambers N, Bishop C (2018) A new outlook on cholinergic interneurons in Parkinson\u2019s disease and L-DOPA-induced dyskinesia. Neurosci Biobehav Rev 92:67\u201382","journal-title":"Neurosci Biobehav Rev"},{"key":"8326_CR82","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.neulet.2018.02.042","volume":"672","author":"S Leino","year":"2018","unstructured":"Leino S, Koski SK, Rannanp\u00e4\u00e4 S, Salminen O (2018) Effects of antidyskinetic nicotine treatment on dopamine release in dorsal and ventral striatum. Neurosci Lett 672:40\u201345","journal-title":"Neurosci Lett"},{"key":"8326_CR83","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.neuropharm.2013.06.005","volume":"73","author":"TH Johnston","year":"2013","unstructured":"Johnston TH, Huot P, Fox SH, Koprich JB, Szeliga KT, James JW et al (2013) TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque. Neuropharmacology 73:337\u2013347","journal-title":"Neuropharmacology"},{"key":"8326_CR84","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.neuroscience.2019.04.008","volume":"409","author":"NE Chambers","year":"2019","unstructured":"Chambers NE, Meadows SM, Taylor A, Sheena E, Lanza K, Conti MM et al (2019) Effects of muscarinic acetylcholine m1 and m4 receptor blockade on dyskinesia in the hemi-parkinsonian rat. Neuroscience 409:180\u2013194","journal-title":"Neuroscience"},{"issue":"2","key":"8326_CR85","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2174\/1570159X16666180302115032","volume":"17","author":"S Jamwal","year":"2019","unstructured":"Jamwal S, Kumar P (2019) Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson\u2019s Disease and Huntington\u2019s Disease: A Review. Curr Neuropharmacol 17(2):165\u2013175","journal-title":"Curr Neuropharmacol"},{"issue":"Pt 5","key":"8326_CR86","first-page":"1075","volume":"127","author":"F Calon","year":"2004","unstructured":"Calon F, Dridi M, Hornykiewicz O, B\u00e9dard PJ, Rajput AH, Di Paolo T (2004) Increased adenosine A2A receptors in the brain of Parkinson\u2019s disease patients with dyskinesias. J Neurol 127(Pt 5):1075\u20131084","journal-title":"J Neurol"},{"key":"8326_CR87","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.brainres.2010.08.099","volume":"1367","author":"D Xiao","year":"2011","unstructured":"Xiao D, Cassin JJ, Healy B, Burdett TC, Chen JF, Fredholm BB et al (2011) Deletion of adenosine A1 or A(2A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson\u2019s disease. Brain Res 1367:310\u2013318","journal-title":"Brain Res"},{"issue":"5","key":"8326_CR88","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/ncn3.12415","volume":"8","author":"N Kanzato","year":"2020","unstructured":"Kanzato N, Nakachi K, Naka T, Mochizuki S, Miyamae Y, Okada Y (2020) Parkinson\u2019s disease therapy with Istradefylline and blood biomarkers of epigenetics. Neurol Clin Neurosci 8(5):276\u2013283","journal-title":"Neurol Clin Neurosci"},{"issue":"11","key":"8326_CR89","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.biopsych.2010.01.024","volume":"67","author":"M Egeland","year":"2010","unstructured":"Egeland M, Warner-Schmidt J, Greengard P, Svenningsson P (2010) Neurogenic effects of fluoxetine are attenuated in p11 (S100A10) knockout mice. Biol Psychiat 67(11):1048\u20131056","journal-title":"Biol Psychiat"},{"issue":"12","key":"8326_CR90","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.3390\/ijms19124122","volume":"19","author":"TM Noye","year":"2018","unstructured":"Noye TM, Lokman NA, Oehler MK, Ricciardelli C (2018) S100A10 and cancer hallmarks: structure, functions, and its emerging role in ovarian cancer. Int J Mol Sci 19(12):4122","journal-title":"Int J Mol Sci"},{"issue":"11","key":"8326_CR91","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/pin.12861","volume":"69","author":"Y Saiki","year":"2019","unstructured":"Saiki Y, Horii A (2019) Multiple functions of S100A10, an important cancer promoter. Pathol Int 69(11):629\u2013636","journal-title":"Pathol Int"},{"issue":"6","key":"8326_CR92","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1007\/s13277-013-0962-1","volume":"34","author":"J Shang","year":"2013","unstructured":"Shang J, Zhang Z, Song W, Zhou B, Zhang Y, Li G et al (2013) S100A10 as a novel biomarker in colorectal cancer. Tumor Biol 34(6):3785\u20133790","journal-title":"Tumor Biol"},{"issue":"1","key":"8326_CR93","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13048-019-0592-3","volume":"12","author":"L Wang","year":"2019","unstructured":"Wang L, Yan W, Li X, Liu Z, Tian T, Chen T et al (2019) S100A10 silencing suppresses proliferation, migration and invasion of ovarian cancer cells and enhances sensitivity to carboplatin. J Ovarian Res 12(1):113","journal-title":"J Ovarian Res"},{"issue":"4","key":"8326_CR94","doi-asserted-by":"publisher","first-page":"826","DOI":"10.7150\/jca.36203","volume":"11","author":"C Li","year":"2020","unstructured":"Li C, Ma Y, Fei F, Zheng M, Li Z, Zhao Q et al (2020) Critical role and its underlying molecular events of the plasminogen receptor, S100A10 in malignant tumor and non-tumor diseases. J Cancer 11(4):826\u2013836","journal-title":"J Cancer"},{"issue":"1430","key":"8326_CR95","doi-asserted-by":"publisher","first-page":"559486","DOI":"10.3389\/fcell.2020.559486","volume":"8","author":"Y Li","year":"2020","unstructured":"Li Y, Li X-Y, Li L-X, Zhou R-C, Sikong Y, Gu X et al (2020) S100A10 Accelerates aerobic glycolysis and malignant growth by activating mTOR-signaling pathway in gastric cancer. Front Cell Dev Biol 8(1430):559486","journal-title":"Front Cell Dev Biol"},{"issue":"21","key":"8326_CR96","doi-asserted-by":"publisher","first-page":"6676","DOI":"10.1158\/0008-5472.CAN-11-1748","volume":"71","author":"KD Phipps","year":"2011","unstructured":"Phipps KD, Surette AP, O\u2019Connell PA, Waisman DM (2011) Plasminogen receptor S100A10 is essential for the migration of tumor-promoting macrophages into tumor sites. Can Res 71(21):6676\u20136683","journal-title":"Can Res"},{"issue":"2","key":"8326_CR97","first-page":"1417","volume":"17","author":"NA Tantyo","year":"2019","unstructured":"Tantyo NA, Karyadi AS, Rasman SZ, Salim MRG, Devina A, Sumarpo A (2019) The prognostic value of S100A10 expression in cancer (Review). Oncol Lett 17(2):1417\u20131424","journal-title":"Oncol Lett"},{"key":"8326_CR98","doi-asserted-by":"publisher","DOI":"10.1172\/JCI151803","author":"W Zhang","year":"2022","unstructured":"Zhang W, Xiao D, Li X, Zhang Y, Rasouli J, Casella G et al (2022) SIRT1 inactivation switches reactive astrocytes to an antiinflammatory phenotype in CNS autoimmunity. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI151803","journal-title":"J Clin Invest"},{"issue":"8","key":"8326_CR99","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00702-018-1874-4","volume":"125","author":"A Pisanu","year":"2018","unstructured":"Pisanu A, Boi L, Mulas G, Spiga S, Fenu S, Carta AR (2018) Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function. J Neural Transm 125(8):1287\u20131297","journal-title":"J Neural Transm"},{"key":"8326_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.625166","author":"A Yan","year":"2021","unstructured":"Yan A, Song L, Zhang Y, Wang X, Liu Z (2021) Systemic Inflammation Increases the Susceptibility to Levodopa-Induced Dyskinesia in 6-OHDA Lesioned Rats by Targeting the NR2B-Medicated PKC\/MEK\/ERK Pathway. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2020.625166","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"8326_CR101","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/imm.12233","volume":"142","author":"S Amor","year":"2014","unstructured":"Amor S, Peferoen LA, Vogel DY, Breur M, van der Valk P, Baker D et al (2014) Inflammation in neurodegenerative diseases\u2013an update. Immunology 142(2):151\u2013166","journal-title":"Immunology"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-08326-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-023-08326-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-08326-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T04:10:44Z","timestamp":1702008644000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-023-08326-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":101,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["8326"],"URL":"https:\/\/doi.org\/10.1007\/s11033-023-08326-3","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"type":"print","value":"0301-4851"},{"type":"electronic","value":"1573-4978"}],"subject":[],"published":{"date-parts":[[2023,2,28]]},"assertion":[{"value":"11 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable to this section.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable to this section.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable to this section.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Yes.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}